Kygevvi is a drug owned by Ucb Inc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Kygevvi's patents will be open to challenges from 03 November, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 19, 2040. Details of Kygevvi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11649259 | Polymorphic Forms Of Deoxycytidine, Compositions Comprising The Same And Uses |
Aug, 2040
(14 years from now) | Active |
| US10471087 | Deoxynucleoside Therapy For Diseases Caused By Unbalanced Nucleotide Pools Including Mitochondrial Dna Depletion Syndromes |
Aug, 2036
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Kygevvi's patents.
Latest Legal Activities on Kygevvi's Patents
Given below is the list of recent legal activities going on the following patents of Kygevvi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) | 17 Jan, 2025 | US10471087 |
| Mail Patent eGrant Notification | 16 May, 2023 | US11649259 |
| Recordation of Patent eGrant | 16 May, 2023 | US11649259 |
| Patent eGrant Notification | 16 May, 2023 | US11649259 |
| Recordation of Patent Grant Mailed | 16 May, 2023 | US11649259 |
| Patent Issue Date Used in PTA Calculation | 16 May, 2023 | US11649259 |
| Electronic Review | 16 May, 2023 | US11649259 |
| Email Notification | 16 May, 2023 | US11649259 |
| Email Notification | 27 Apr, 2023 | US11649259 |
| Electronic Review | 27 Apr, 2023 | US11649259 |
FDA has granted several exclusivities to Kygevvi. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Kygevvi, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Kygevvi.
Exclusivity Information
Kygevvi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Kygevvi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 03, 2030 |
US patents provide insights into the exclusivity only within the United States, but
Kygevvi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Kygevvi's family patents as well as insights into
ongoing legal events
on those patents.
Kygevvi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kygevvi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 19, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kygevvi Generics:
There are no approved generic versions for Kygevvi as of now.
About Kygevvi
Kygevvi is a drug owned by Ucb Inc. Kygevvi uses Doxecitine; Doxribtimine as an active ingredient. Kygevvi was launched by Ucb in 2025.
Approval Date:
Kygevvi was approved by FDA for market use on 03 November, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Kygevvi is 03 November, 2025, its NCE-1 date is estimated to be 03 November, 2029.
Active Ingredient:
Kygevvi uses Doxecitine; Doxribtimine as the active ingredient. Check out other Drugs and Companies using Doxecitine; Doxribtimine ingredient
Dosage:
Kygevvi is available in for solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2GM/PACKET;2GM/PACKET | FOR SOLUTION | Prescription | ORAL |